RxDoctor Payments Data

Lindsay Glorioso

Family · Bradenton, FLNPI 1366989915

Payments from drug & device makers

$2,001in general payments, 2019–2025

Across 77 payments — averaging $25.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$543
  • KCI USA, Inc.$432
  • AbbVie$265
  • Kerecis Limited$90
  • Solventum Corporation$88
  • Organogenesis Inc.$85
  • plus $498 from 12 others

What the payments were for

  • Consulting fees$25012%
  • Food & beverage$1,74187%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,001 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$34,518
Medicare patients
155
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.25$15,430
Gentamicin Sulfate35$1,089
Lidocaine12$450
Mupirocin32$291
Cephalexin30$218
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$192
Nystatin16$158
Doxycycline Hyclate19$132
Triamcinolone Acetonide17$117
Hydrocortisone11$83
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim20$51
Ciprofloxacin Hcl15$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$543$15,43025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.

Other family in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →